Undisclosed First-in-Class Programs
Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn’s Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, Sjögren’s Syndrome
Key Facts
About IMIDomics
IMIDomics is a private, clinical-stage biotechnology company founded in 2007 and headquartered in San Francisco. It has built a unique, data-driven discovery and development platform centered on a proprietary biobank and deep clinical dataset from over 17,000 IMID patients and controls, collected over 17 years across a network of clinical centers. The company is using this platform to build a pipeline of first-in-class therapeutic candidates and companion biomarkers, aiming to improve outcomes for patients who do not respond to current therapies. Backed by experienced leadership and strategic partners, IMIDomics operates at the intersection of immunology, genetics, and bioinformatics.
View full company profile